^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
KRAS-EphA-2-CAR-DC
i
Other names: KRAS-EphA-2-CAR-DC, Autologous EphA-2-Targeting Chimeric Antigen Receptor Dendritic Cell Vaccine Loaded With KRAS Mutant Peptide
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Chinese PLA General Hospital
Drug class:
Dendritic cell activator, EphA2 inhibitor
Related drugs:
10ms
CAR-DC Vaccine and ICIs in Local Advanced/Metastatic Solid Tumors (clinicaltrials.gov)
P1, N=15, Recruiting, Chinese PLA General Hospital | N=10 --> 15
Enrollment change • Combination therapy • IO biomarker • Metastases
|
KRAS (KRAS proto-oncogene GTPase)
|
PD-L1 expression • KRAS mutation • MSI-H/dMMR • KRAS G12C • KRAS G12D • KRAS G12V • KRAS G12
|
Yervoy (ipilimumab) • albumin-bound paclitaxel • cyclophosphamide • KRAS-EphA-2-CAR-DC
almost2years
Combination of CAR-DC Vaccine and Anti-PD-1 Antibody in Local Advanced/Metastatic Solid Tumors (clinicaltrials.gov)
P1, N=10, Recruiting, Chinese PLA General Hospital | N=20 --> 10
Enrollment change • Combination therapy • IO biomarker • Metastases
|
KRAS (KRAS proto-oncogene GTPase) • IL6 (Interleukin 6) • IL2 (Interleukin 2) • IL10 (Interleukin 10)
|
PD-L1 expression • KRAS mutation • MSI-H/dMMR • KRAS G12C • KRAS G12D • KRAS G12V • KRAS G12
|
albumin-bound paclitaxel • cyclophosphamide • KRAS-EphA-2-CAR-DC
2years
Combination of CAR-DC Vaccine and Anti-PD-1 Antibody in Local Advanced/Metastatic Solid Tumors (clinicaltrials.gov)
P1, N=20, Recruiting, Chinese PLA General Hospital
New P1 trial • Combination therapy • IO biomarker • Metastases
|
KRAS (KRAS proto-oncogene GTPase) • IL6 (Interleukin 6) • IL2 (Interleukin 2) • IL10 (Interleukin 10)
|
PD-L1 expression • KRAS mutation • MSI-H/dMMR • KRAS G12C • KRAS G12D • KRAS G12V • KRAS G12
|
albumin-bound paclitaxel • cyclophosphamide • KRAS-EphA-2-CAR-DC
Share via
